The case for & against
Bull & Bear analysis
Bearish
Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX) is a leading provider of healthcare information technology solutions specializing in integrated clinical, financial, and operational solutions for healthcare providers, payers, and life sciences companies. The company is gaining traction in the digital health space, leveraging its Veridigm platform to streamline patient engagement and clinical workflows. With a notable pivot towards payer and life sciences segments, Allscripts aims to capitalize on the ongoing shift towards value-based care.
Bull says
- ↑New bookings up 10% YoY, reflecting strong Veridigm demand.
- ↑Q revenue $374 M and adjusted EBITDA +27% demonstrate operational strength.
- ↑Free cash flow of $51 M and 0.46% dividend yield support shareholder returns.
- ↑EBITDA margin expanded to 23.9%, showing effective cost management.
- ↑PRA Health and Microsoft Azure partnerships broaden clinical network.
- ↑Positive macro sensitivity to interest rates and oil prices may boost spending.
Bear says
- ↓Elevated leverage risk from significant debt amid rising interest rates.
- ↓Recent data breach heightens regulatory, reputational, and client risks.
- ↓Hospital segment sees client attrition and unpredictable deal timing.
- ↓Labor costs, the largest expense, compress EBITDA and margin outlook.
- ↓$250 M buyback plan may divert capital from growth initiatives.
- ↓Weak profitability factors and high short interest signal downside risk.
Earnings Call · Q2 2021 · Mgmt. Guidance
Updated 09-10-2026bullish
Transcript signals
Bull points
- So we think that they're in very good shape from that. As far as opportunities for Veridigm on that, I don't see a direct link right now, Charles, but it doesn't mean we won't see one emerge right now from those rules in particular.
- You're expecting Veridigm to grow double digits this year.
- our life sciences leg is getting a lot of traction right now and is becoming a fundamental pillar for drug discovery, which is riding a wave of interest in the life science space.
Bear points
- we still experienced residual delays in closing some new deals, particularly with large health systems markets and in international regions where the recovery from the pandemic has been more uneven.
Read full transcript analysis ›